Safety of β-hydroxybutyrate salts as a novel food pursuant to Regulation (EU) 2015/2283

EFSA J. 2022 Oct 13;20(10):e07449. doi: 10.2903/j.efsa.2022.7449. eCollection 2022 Oct.

Abstract

Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on β-hydroxybutyrate (BHB) salts as a novel food (NF) pursuant to Regulation (EU) 2015/2283. The NF consists of sodium, magnesium and calcium BHB salts, and is proposed to be used by adults as a food ingredient in a number of food categories and as food supplement. The data provided by the applicant about the identity, the production process and the compositional data of the NF over the course of the risk assessment period were overall considered unsatisfactory. The Panel noted inconsistencies in the reporting of the test item used in the subchronic toxicity study and human studies provided by the applicant. Owing to these deficiencies, the Panel cannot establish a safe intake level of the NF. The Panel concludes that the safety of the NF has not been established.

Keywords: calcium; chemical synthesis; food supplements; magnesium; novel food; sodium; β‐hydroxybutyrate.